These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37748190)

  • 1. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
    Papavassiliou KA; Sofianidi AA; Papavassiliou AG
    J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors.
    Akrida I; Makrygianni M; Nikou S; Mulita F; Bravou V; Papadaki H
    Pathol Res Pract; 2024 Oct; 262():155551. PubMed ID: 39153238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
    Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
    Elife; 2022 Oct; 11():. PubMed ID: 36300789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 10. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of
    Tang TT; Konradi AW; Feng Y; Peng X; Ma M; Li J; Yu FX; Guan KL; Post L
    Mol Cancer Ther; 2021 Jun; 20(6):986-998. PubMed ID: 33850002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
    Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
    Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
    Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
    Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ.
    Kwon H; Kim J; Jho EH
    FEBS J; 2022 Oct; 289(19):5798-5818. PubMed ID: 34173335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the Hippo-YAP/TAZ Pathway in Epithelioid Hemangioendothelioma and its Potential as a Therapeutic Target.
    Suto H
    Anticancer Res; 2024 Oct; 44(10):4147-4153. PubMed ID: 39348982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
    Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
    Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of signaling pathways regulating YAP/TAZ activity.
    Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
    Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
    Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
    Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.